Machine learning reveals distinct T-cell receptor clusters in plasma cell dyscrasias compared to healthy controls
Fig 2
T-cell receptor β chain (TCRB) clonality is not significantly associated with disease burden or depth of treatment response. A) Comparison of TCRB clonality (Gini coefficient) between 44 healthy individuals (age > 40 years) and patients with monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and multiple myeloma (MM). P-values of significant differences in the univariate analysis (Wilcoxon test) are shown. No significant differences were observed in the multivariate linear model that corrected for age. B) TCRB clonality in MGUS patients at baseline and follow-up (median follow-up 677 days). C) TCRB clonality in MM patients before treatment, stratified by post-treatment depth of response. D) TCRB clonality in SMM patients undergoing carfilzomib, lenalidomide, and dexamethasone (KRd) shown for the entire cohort, and E) stratified by depth of response. F) Line plot comparing the change in individual TCRB clonality among SMM patients undergoing KRd treatment. MRD, minimal residual disease; CR, complete response; VGPR, very good partial response; PR, partial response.